NCT05636787
Clinical Trial Investigating the Chemotherapeutic Compound Treosulfan (Trecondi® Ideogen) in Myeloma Patients
Recruiting · Phase 2 · Insel Gruppe AG, University Hospital Bern · registry updated 2024-07-08
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
Clinical trial investigating the chemotherapeutic compound treosulfan (Trecondi® Ideogen) in myeloma patients.
Inclusion
- Eligible are myeloma patients after standard first-line induction treatment. Additional induction regimens in refractory myeloma patients are allowed.
- Patients must be considered fit for subsequent consolidation with high-dose chemotherapy with autologous stem cell transplantation.
- Patients must be aged 18-75 years.
- Patients must have an ECOG \<3.
- Patients must have a creatinine clearance ≥35 ml/min.
- Patients must have an LVEF ≥40% within three months prior to start of study HDCT.
Exclusion
- Patients with an uncontrolled acute infection.
- Patients with a transplantation comorbidity index (HCTCI) \> 6 points.
- Patients with concurrent active malignant disease with the exception of basalioma/spinalioma of the skin or early-stage cervix carcinoma, or early-stage prostate cancer. Previous treatment for other malignancies (not listed above) must have been terminated at least 6 months before registration and no evidence of active disease may be documented since then.
- Patients with major coagulopathy or bleeding disorder.
- Patients with other medical conditions that could potentially interfere with the completion of treatment according to this protocol or that would impair tolerance to therapy or prolong hematological recovery.
- Lack of patient cooperation to allow study treatment as outlined in this protocol.